Please login to the form below
Anaveon
This page shows the latest Anaveon news and features for those working in and with pharma, biotech and healthcare.
Novartis and Syncona back new Swiss biotech Anaveon
Founders focused on IL-2 Receptor Agonists. Novartis' venture fund arm and Syncona are supporting new Switzerland-based immuno-oncology specialists Anaveon. ... re-direction of IL-2 activity in vivo, Anaveon has developed biologic approaches for the
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- FDA approves Roche’s Actemra COVID-19 trial
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
